Data gathered: November 22
AI Stock Analysis - Novavax (NVAX)
Analysis generated November 20, 2024. Powered by Chat GPT.
Novavax, Inc. is a biotechnology company that specializes in the research, development, and commercialization of vaccines to prevent serious infectious diseases. The company has been prominent in the COVID-19 vaccine development arena with its NVX-CoV2373 vaccine candidate. Over the years, Novavax has worked on various vaccines, seeking to bring innovative solutions to the market.
Stock Alerts - Novavax (NVAX)
 |
Novavax | November 18 Price is up by 6.8% in the last 24h. |
|
Novavax | November 14 Price is down by -5.3% in the last 24h. |
|
Novavax | November 13 Web Traffic is down by 35.6% over the last month. |
|
Novavax | November 13 Price is down by -5.3% in the last 24h. |
Alternative Data for Novavax
| Alternative Data | Value | 3m Change | Trend | Benchmark |
|---|---|---|---|---|
| Job Posts | 5 | Sign up | Sign up | Sign up |
| Sentiment | 95 | Sign up | Sign up | Sign up |
| Webpage traffic | 48,000 | Sign up | Sign up | Sign up |
| Employee Rating | 60 | Sign up | Sign up | Sign up |
| Google Trends | 28 | Sign up | Sign up | Sign up |
| Patents | 38 | Sign up | Sign up | Sign up |
| 4chan Mentions | N/A | Sign up | Sign up | Sign up |
| Facebook Engagement | 3,131 | Sign up | Sign up | Sign up |
| Facebook Followers | 40,669 | Sign up | Sign up | Sign up |
| Reddit Mentions | N/A | Sign up | Sign up | Sign up |
| Stocktwits Mentions | 65 | Sign up | Sign up | Sign up |
| Stocktwits Subscribers | 101,971 | Sign up | Sign up | Sign up |
| Twitter Followers | 61,684 | Sign up | Sign up | Sign up |
| Twitter Mentions | 58 | Sign up | Sign up | Sign up |
| Youtube Subscribers | 1,140 | Sign up | Sign up | Sign up |
| News Mentions | N/A | Sign up | Sign up | Sign up |
| Customer reviews | N/A | Sign up | Sign up | Sign up |
| ESG | 31 | Sign up | Sign up | Sign up |
| Lobbying Cost | $30,000 | Sign up | Sign up | Sign up |
| Business Outlook | 17 | Sign up | Sign up | Sign up |
| Linkedin Employees | 1,412 | Sign up | Sign up | Sign up |
About Novavax
Novavax, Inc. is an American biotechnology company based in Gaithersburg, Maryland that develops vaccines to counter serious infectious diseases. Prior to 2020, company scientists developed experimental vaccines for influenza and respiratory syncytial virus, as well as Ebola and other emerging infectious diseases.
| Price | $8.04 |
| Target Price | Sign up |
| Volume | 3,120,000 |
| Market Cap | $1.29B |
| Year Range | $3.89 - $20.97 |
| Dividend Yield | 0% |
| Analyst Rating | 50% buy |
| Industry | Biotechnology |
In the news
 |
Novavax, Inc. (NVAX) Jefferies London Healthcare Conference (Transcript)November 19 - SeekingAlpha |
 |
FY2024 Earnings Estimate for Novavax Issued By HC WainwrightNovember 18 - ETF Daily News |
Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novavax, Inc. - NVAXNovember 18 - Finnhub |
|
 |
Analyzing Ginkgo Bioworks (NYSE:DNA) & Novavax (NASDAQ:NVAX)November 17 - ETF Daily News |
 |
Investors Heavily Search Novavax, Inc. (NVAX): Here is What You Need to KnowNovember 17 - Yahoo |
Novavax Announces Grant of Inducement Awards Pursuant to Nasdaq Listing Rule 5635(4)November 17 - Finnhub |
|
Financial performance View All
| Revenue | Cost of Revenue | Gross Profit | Net Income | ebitda | EPS | |
|---|---|---|---|---|---|---|
| Q3 '24 | 85M | 61M | 24M | -121M | -107M | -0.758 |
| Q2 '24 | 415M | 46M | 369M | 162M | 178M | 0.990 |
| Q1 '24 | 94M | 59M | 35M | -148M | -129M | -1.050 |
| Q4 '23 | 291M | 155M | 136M | -178M | -162M | -1.440 |
| Q3 '23 | 187M | 99M | 88M | -131M | -117M | -1.260 |
Insider Transactions View All
| YOUNG JAMES F filed to sell 61,760 shares at $14.1. June 25 '24 |
| YOUNG JAMES F filed to sell 69,260 shares at $14.3. June 21 '24 |
| YOUNG JAMES F filed to sell 70,367 shares at $13.6. June 21 '24 |
| Dubovsky Filip filed to sell 66,613 shares at $14.5. June 20 '24 |
| Dubovsky Filip filed to sell 68,017 shares at $14.5. June 20 '24 |
Similar companies
Read more about Novavax (NVAX) and their ai stock analysis, price prediction, earnings, congress trading, insider transactions, technical analysis, job posts, sentiment, webpage traffic, employee rating, google trends, patents, 4chan mentions, facebook engagement, facebook followers, reddit mentions, stocktwits mentions, stocktwits subscribers, twitter followers, twitter mentions, youtube subscribers, news mentions, customer reviews, lobbying cost, business outlook & linkedin employees.
What is the Market Cap of Novavax?
The Market Cap of Novavax is $1.29B.
What is the current stock price of Novavax?
Currently, the price of one share of Novavax stock is $8.04.
How can I analyze the NVAX stock price chart for investment decisions?
The NVAX stock price chart above provides a comprehensive visual representation of Novavax's stock performance over time. Investors can use this chart to identify patterns, trends, and potential support or resistance levels. By examining historical data and recent price movements, investors can make more informed decisions regarding buying, holding, or selling Novavax shares. Our platform offers an up-to-date NVAX stock price chart, along with technical data analysis and alternative data insights.
Does NVAX offer dividends to its shareholders?
As of our latest update, Novavax (NVAX) does not offer dividends to its shareholders. Investors interested in Novavax should consider the potential for capital appreciation as the primary return on investment, rather than expecting dividend payouts.
What are some of the similar stocks of Novavax?
Some of the similar stocks of Novavax are Amgen, Gilead Sciences, Catalyst Pharmaceuticals, Inovio Pharmaceuticals, and Anavex Life Sciences.
.